Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT07114653
Recruiting Observational

The Role of POLE Mutation in High Risk Endometrial Cancer.

NCT07114653 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Far Eastern Memorial Hospital
Phase
Observational
Started
2025-09-01
Last updated
2025-08-11

Condition(s) studied

Endometrial Neoplasms

Study summary

The actual role of POLE mutations in high-risk endometrial cancer is undetermined. The main question it aims to answer is:

What is the prevalence of POLE mutations in high-risk endometrial cancer case? What is the impact of POLE mutations in real world high-risk endometrial cancer case?

Eligibility

Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * women with high-risk for recurrent endometrial cancer Exclusion Criteria: * Nil

Primary outcome measure(s)

  • Prevalence of POLE mutation in high risk endometrial cancer — 2 years
    The prevalence of POLE mutations in women with high-risk for recurrent endometrial cancer

Trial sites (1)

FacilityCityRegionStatus
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital Banqiao District New Taipei Recruiting

More Far Eastern Memorial Hospital trials in Taiwan

Clinical Outcomes of Non-Indicated Staged Laparotomies in Abdominal Trauma Starting soon
Effect of Dialysis-specific Therapeutic Diet on Biochemical Parameters in Dialysis Patients Active, not recruiting
Exploring the Relationship Between Mini-Clinical Evaluation Exercise (Mini-CEX) and Entrustable Professional Activities (EPAs) in Occupational Therapy Clinical Interns' Independent Competence Starting soon
Exploring the Feasibility of Transcranial Ultrasound Stimulation in the Treatment of Schizophrenia Recruiting
The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients Starting soon

Other trials for the same condition

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) Active, not recruiting
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor Active, not recruiting
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer Starting soon
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) Recruiting
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07114653 on ClinicalTrials.gov ↗ ← All trials in Taiwan